Browse the corpus

JH has received funding in the form of a research fellowship from the CW+ charity and The Westminster Medical School Research Trust; and has received honoraria from Gilead, unrelated to this Correspondence. SJCP has received a research grant from the Scientific Exploration Society–Viscount Gough, unrelated to this Correspondence. NM has received speaker fees from Beyer and Pfizer; and received educational support from Eumedica and Baxter. GWD has received consultation fees from DNA Nudge. LSPM has consulted for and received speaker fees from bioMerieux, Pfizer, Eumedica, Shionogi, Pulmocide, Umovis Labs, DNA Electronics, Profile Pharma, and Dairy Crest; and received research grants from the UK National Institute for Health Research (NIHR), LifeArc, and the CW+ charity. RJ has received honoraria, speaker fees, travel support, or research grant funding from Gilead, ViiV Healthcare, Bristol Myers Squibb, Abbvie, Janssen, and Merck. All other authors declare no competing interests. JH acknowledges support from the CW+ charity and The Westminster Medical School Research Trust. LSPM acknowledges support from the NIHR, Imperial Biomedical Research Centre, and the NIHR Health Protection Research Unit in health-care associated infection and antimicrobial resistance at Imperial College London, in partnership with Public Health England. The views expressed in this Correspondence are those of the authors, and not necessarily those of the National Health Service, the NIHR, or the UK Department of Health.